Resolute Integrity cardiac stent non-inferior to everolimus stent - Medtronic

The novel cobalt-chromium-based zotarolimus-eluting stent (ZES) ReSolute Integrity stent from Medtronic is non-inferior to a platinum-chromium-based everolimus- eluting stent (EES), according to a paper comparing the two third-generation devices published online February 2, 2014, ahead of print in The Lancet.

Results from the all-comer DUTCH PEERS (Durable polymer-based stent Challenge of Promus ElemEnt versus ReSolute Integrity) trial were previously presented at the annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco, CA, in October 2013.

Researchers led by Clemens von Birgelen, MD, PhD, of Thoraxcentrum Twente (Enschede, the Netherlands), randomized 1,811 patients (n = 2,371 target lesions) to third-generation Resolute Integrity ZES (n = 906; Medtronic, Santa Rosa, CA) or Promus Element EES (n = 905; Boston Scientific, Natick, MA) in the single-blind trial at 4 study sites in the Netherlands from November 2010-May 2012. Resolute Integrity �uses a novel, open-cell stent design for increased flexibility and deliverability,� the paper reports, while the Promus Element �is designed for improved deliverability and visibility (ie, radiopacitiy).� Noninferiority was determined 1 year postprocedure with a primary endpoint of target-vessel failure (TVF; defined as: cardiac death, target vessel-related MI, or clinically indicated TVR)